ADMA Biologics is an end-to-end commercial biopharmaceutical company that is leading the way in manufacturing, marketing, and commercializing specialty plasma-derived products. Their focus is on preventing and treating infectious diseases in immune-compromised patients and those at risk for certain infections. With a strong commitment to underserved populations, ADMA Biologics sets itself apart through its hands-on approach to production and development.

The company offers three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®, which are all immune globulin products. These products are targeted to specific patient populations for the treatment and prevention of infectious diseases and the management of immune-compromised patient populations. ADMA Biologics is the only US-domiciled producer of plasma-derived therapeutics and has a rapidly growing and diversified commercial product portfolio.

They also have a strong patent portfolio and a world-class, cGMP-compliant biologics manufacturing plant, ensuring an uninterrupted supply chain. Through their commitment to improving patients' lives, ADMA Biologics is at the forefront of the immunotechnology industry